FDA Clears Genetic Lab Test For Warfarin Sensitivity

Armen Hareyan's picture
Advertisement

Warfarin

Advertisement

FDA cleared for marketing a new genetic test that will help physicians assess whether a patient may be especially sensitive to the blood-thinning drug warfarin (Coumadin), which is used to prevent potentially fatal clots in blood vessels.

One-third of patients receiving warfarin metabolize it quite differently than expected and experience a higher risk of bleeding. Research has shown that some of the unexpected response to warfarin depends on variants of two genes, CYP2C9 and VKORC1. The Nanosphere Verigene Warfarin Metabolism Nucleic Acid Test detects some variants of both genes.

"Today

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement